Auswirkungen einer SARS-CoV-2-Infektion auf Symptomatik und Therapie chronisch-entzündlicher Darmerkrankungen

Zusammenfassung

Einleitung Der Einfluss einer SARS-CoV-2-Infektion auf chronisch entzündliche Darmerkrankungen (CED) ist bislang nicht gut charakterisiert, und es ist unklar, ob diese eine Anpassung der immunsuppressiven Therapie erfordert.

Methodik Für die retrospektive Dokumentation klinischer Parameter und Veränderungen einer immunsuppressiven Therapie von mit SARS-CoV-2 infizierten CED-Patienten wurde ein nationales Melderegister etabliert.

Ergebnisse Insgesamt wurden nur 3 von 185 CED-Patienten (1,6 %) wegen abdomineller Symptome auf eine SARS-CoV-2-Infektion getestet. Im COVID-19-Krankheitsverlauf entwickelten 43,5 % Durchfall, abdominelle Schmerzen oder Hämatochezie (Hospitalisierungsrisiko mit vs. ohne abdominelle Symptome: 20,0 % vs. 10,6 %, p < 0,01). Bei aktiver CED zum Zeitpunkt des SARS-CoV-2-Nachweises bestand ein erhöhtes Hospitalisierungsrisiko (Remission 11,2 %, aktive CED 23,3 % p < 0,05). Die CED-spezifische Therapie blieb bei 115 Patienten (71,4 %) unverändert; die häufigste Änderung bestand in einer Unterbrechung der systemischen Therapie (16,2 %).

Diskussion Bei mit SARS-CoV-2 infizierten CED-Patienten traten häufig neue abdominelle Symptome bei Infektion auf. Diese führten aber nur selten zur SARS-CoV-2-Testung. Eine hohe CED-Aktivität zum Zeitpunkt des SARS-CoV-2-Nachweises war mit einem erhöhten Hospitalisierungsrisiko assoziiert.

Abstract

Introduction The influence of a SARS-CoV-2 infection on inflammatory bowel disease (IBD) has not yet been well characterized and it is unclear whether this requires an adaptation of the immunosuppressive therapy.

Methods A national register was established for the retrospective documentation of clinical parameters and changes in immunosuppressive therapy in SARS-CoV-2 infected IBD patients.

Results In total, only 3 of 185 IBD patients (1.6 %) were tested for SARS-CoV-2 infection because of abdominal symptoms. In the course of COVID-19 disease, 43.5 % developed diarrhea, abdominal pain or hematochezia (risk of hospitalization with vs. without abdominal symptoms: 20.0 % vs. 10.6 %, p < 0.01). With active IBD at the time of SARS-CoV-2 detection, there was an increased risk of hospitalization (remission 11.2 %, active IBD 23.3 % p < 0.05). IBD-specific therapy remained unchanged in 115 patients (71.4 %); the most common change was an interruption of systemic therapy (16.2 %).

Discussion New abdominal symptoms often appeared in SARS-CoV-2 infected IBD patients. However, these only rarely led to SARS-CoV-2 testing. A high IBD activity at the time of SARS-CoV-2 detection was associated with an increased risk of hospitalization.

Schlüsselwörter

Sars-CoV-2 - COVID-19 - chronisch entzündliche Darmerkrankungen - Morbus Crohn - Immunsuppression

Key words

Sars-CoV-2 - COVID-19 - inflammatory bowel diseases - Crohn’s disease - immunosuppression

Publikationsverlauf

Eingereicht: 12. März 2021

Angenommen: 09. Mai 2021

Artikel online veröffentlicht:
16. Juli 2021

• Literatur

• 1 Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit, Robert Koch-Institut. Beschreibung des bisherigen Ausbruchsgeschehens mit dem neuartigen Coronavirus SARS-CoV-2 in Deutschland (Stand: 12. Februar 2020). Epid Bull 2020; 7: 3-4
• 2 Robert Koch-Institut. Aktuelle Statistik meldepflichtiger Infektionskrankheiten 4. Woche 2021 (Datenstand: 3. Februar 2021). Epidemiologisches Bulletin 2021; 5: 81
• 3 Bäuerle A, Teufel M, Musche V. et al. Increased generalized anxiety, depression and distress during the COVID-19 pandemic: a cross-sectional study in Germany. J Public Health (Oxf) 2020; 42: 672-678 DOI: 10.1093/pubmed/fdaa106. (PMID: 32657323)
• 4 Grunert PC, Reuken PA, Stallhofer J. et al. Inflammatory bowel disease in the COVID-19 pandemic – the patients' perspective. J Crohns Colitis 2020; DOI: 10.1093/ecco-jcc/jjaa126. (PMID: 32564068)
• 5 D'Amico F, Rahier JF, Leone S, Peyrin-Biroulet L, Danese S. Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey. Lancet Gastroenterol Hepatol 2020; 5: 631-632 DOI: 10.1016/S2468-1253(20)30151-5. (PMID: 32411920)
• 6 Ungaro RC, Brenner EJ, Gearry RB. et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut 2021; 70 (04) 725-732 DOI: 10.1136/gutjnl-2020-322539. (PMID: 33082265)
• 7 Brenner EJ, Ungaro RC, Colombel JF, Kappelman MD. SECURE-IBD Database Public Data Update. COVIDibd.org. Accessed on 12.02.21.
• 8 Peiris JS, Chu CM, Cheng VC. et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003; 361: 1767-1772 DOI: 10.1016/s0140-6736(03)13412-5. (PMID: 12781535)
• 9 Bwire GM, Majigo MV, Njiro BJ, Mawazo A. Detection profile of SARS-CoV-2 using RT-PCR in different types of clinical specimens: A systematic review and meta-analysis. J Med Virol 2021; 93: 719-725 DOI: 10.1002/jmv.26349. (PMID: 32706393)
• 10 Lamers MM, Beumer J, van der Vaart J. et al. SARS-CoV-2 productively infects human gut enterocytes. Science 2020; 369: 50-54 DOI: 10.1126/science.abc1669. (PMID: 32358202)
• 11 Schenk W, Klugmann T, Borkenhagen A. et al. The detection of the cytomegalovirus DNA in the colonic mucosa of patients with ulcerative colitis is associated with increased long-term risk of proctocolectomy: results from an outpatient IBD clinic. Int J Colorectal Dis 2019; 34: 393-400 DOI: 10.1007/s00384-018-3210-8. (PMID: 30506156)
• 12 Garcia PG, Chebli LA, da Rocha Ribeiro TC. et al. Impact of superimposed Clostridium difficile infection in Crohn's or ulcerative colitis flares in the outpatient setting. Int J Colorectal Dis 2018; 33: 1285-1294 DOI: 10.1007/s00384-018-3105-8. (PMID: 29926235)
• 13 Cheung KS, Hung IFN, Chan PPY. et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic Review and Meta-analysis. Gastroenterology 2020; 159: 81-95 DOI: 10.1053/j.gastro.2020.03.065. (PMID: 32251668)
• 14 Ghimire S, Sharma S, Patel A. et al. Diarrhea is associated with icreased Severity of Disease in COVID-19: Systemic Review and Metaanalysis. SN Compr Clin Med 2021; 6: 1-8
• 15 Gadiparthi C, Perisetti A, Sayana H, Tharian B, Inamdar S, Korman A. Gastrointestinal bleeding in patients with severe SARS-CoV-2. Am J Gastroenterol 2020; 115: 1283-1285 DOI: 10.14309/ajg.0000000000000719. (PMID: 32516204)
• 16 Stallmach A, Sturm A, Blumenstein I. et al. Addendum to S3-Guidelines Crohn’s disease and ulcerative colitis: management of patients with inflammatory bowel disease in the COVID-19 pandemic – open questions and answers. Z Gastroenterol 2020; 58: 982-1002 DOI: 10.1055/a-1234-8079. (PMID: 33036052)
• 17 Hasseli R, Mueller-Ladner U, Hoyer BF. et al. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open 2021; 7: e001464 DOI: 10.1136/rmdopen-2020-001464. (PMID: 33479021)
• 18 Strangfeld A, Schäfer M, Gianfrancesco MA. et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2021; DOI: 10.1136/annrheumdis-2020-219498. (PMID: 33504483)
• 19 Ragni P, Marino M, Formisano D. et al. Association between exposure to influenza vaccination and COVID-19 diagnosis and outcomes. Vaccines (Basel) 2020; 8: 675 DOI: 10.3390/vaccines8040675. (PMID: 33198368)
• 20 Green I, Ashkenazi S, Merzon E, Vinker S, Golan-Cohen A. The association of previous influenza vaccination and coronavirus disease-2019. Hum Vaccin Immunother 2020; 30: 1-7 DOI: 10.1080/21645515.2020.1852010. (PMID: 33377817)
• 21 Ridolfo AL, Milazzo L, Giacomelli A. et al. Low influenza vaccination coverage among hospitalized COVID-19 patients in Milan: A gap to be urgently filled. Eur J Intern Med 2020: S0953–6205(20)30471–4.